BBIO Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 14.23%. BridgeBio Pharma's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 6.29%.

BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 67.83%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.20 which suggests that it could grow by 43.61%. Given that BridgeBio Pharma has higher upside potential than Biomarin Pharmaceutical, analysts believe BridgeBio Pharma is more attractive than Biomarin Pharmaceutical.

BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.112%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. BridgeBio Pharma's net income of -$162M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 40.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 24.66x versus 4.88x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 25.23%. BridgeBio Pharma's return on equity of -- beat Pfizer's return on equity of 4.63%.

BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 67.83%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.3%. Given that BridgeBio Pharma has higher upside potential than Pfizer, analysts believe BridgeBio Pharma is more attractive than Pfizer.

BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.26% to investors and pays a quarterly dividend of $0.42 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Pfizer quarterly revenues of $17.7B. BridgeBio Pharma's net income of -$162M is lower than Pfizer's net income of $4.5B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 24.66x versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of 36.03%. BridgeBio Pharma's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 67.83%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,045.03 which suggests that it could grow by 42.46%. Given that BridgeBio Pharma has higher upside potential than Regeneron Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Regeneron Pharmaceuticals.

BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. BridgeBio Pharma's net income of -$162M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 18.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 24.66x versus 6.10x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -5931.19% compared to BridgeBio Pharma's net margin of --. BridgeBio Pharma's return on equity of -- beat Cassava Sciences's return on equity of --.

BridgeBio Pharma has a consensus price target of $49.43, signalling upside risk potential of 67.83%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4006.2%. Given that Cassava Sciences has higher upside potential than BridgeBio Pharma, analysts believe Cassava Sciences is more attractive than BridgeBio Pharma.

BridgeBio Pharma has a beta of 1.055, which suggesting that the stock is 5.497% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.985, suggesting its less volatile than the S&P 500 by 198.512%.

BridgeBio Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

BridgeBio Pharma quarterly revenues are $2.7M, which are larger than Cassava Sciences quarterly revenues of --. BridgeBio Pharma's net income of -$162M is lower than Cassava Sciences's net income of -$27.9M. Notably, BridgeBio Pharma's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma is 24.66x versus 3.10x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.